MARKET

SGMO

SGMO

Sangamo Therapeutics Inc
NASDAQ
0.4250
-0.0200
-4.49%
After Hours: 0.4248 -0.0002 -0.05% 18:37 12/26 EST
OPEN
0.4399
PREV CLOSE
0.4450
HIGH
0.4419
LOW
0.4200
VOLUME
4.25M
TURNOVER
--
52 WEEK HIGH
2.730
52 WEEK LOW
0.3846
MARKET CAP
143.01M
P/E (TTM)
-0.9598
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at SGMO last week (1215-1219)?
Weekly Report · 6d ago
Sangamo initiates rolling submission of BLA to U.S. FDA for ST-920
TipRanks · 12/18 13:16
Sangamo Therapeutics Initiates Rolling Submission Of BLA To FDA Seeking Accelerated Approval Of Isaralgagene Civaparvovec, Or ST-920, Investigational Gene Therapy For Treatment Of Adults With Fabry Disease
Benzinga · 12/18 13:12
Sangamo Therapeutics Begins FDA Rolling Submission for ST-920 Gene Therapy in Fabry Disease
Reuters · 12/18 13:05
SANGAMO THERAPEUTICS INC - EXPECTS TO COMPLETE BLA SUBMISSION BY Q2 2026
Reuters · 12/18 13:05
Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease
Barchart · 12/18 07:05
Weekly Report: what happened at SGMO last week (1208-1212)?
Weekly Report · 12/15 09:03
Regeneron Pharmaceuticals: Is Wall Street Finally Paying Attention?
Seeking Alpha · 12/08 19:46
More
About SGMO
Sangamo Therapeutics, Inc. is a genomic medicine company. The Company’s zinc finger (ZF) epigenetic regulators are ideally suited to potentially address neurological disorders and its capsid engineering platform has demonstrated the ability to expand delivery beyond available intrathecal delivery capsids, including in the central nervous system (CNS), in preclinical studies. Zinc finger technologies are derived from naturally occurring human proteins. They are composed of a DNA-binding domain, which binds with precision to any sequence of DNA, and various functional domains (such as nucleases and transcription factors) based on therapeutic needs. Its pipeline includes Chronic Neuropathic Pain - ST-503 and Isaralgagene civaparvovec (ST-920). ST-503 is an investigational epigenetic regulator for the treatment of intractable pain due to iSFN, a type of chronic neuropathic pain. ST-920 is a wholly owned gene therapy product candidate for the treatment of Fabry disease.

Webull offers Sangamo Therapeutics Inc stock information, including NASDAQ: SGMO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SGMO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SGMO stock methods without spending real money on the virtual paper trading platform.